(AOF) – Novo Nordisk (-22.90% to 573.00 Danish crowns) falls on the Copenhagen Stock Exchange after the results of its experimental drug against obesity, CagriSema, are considered lower than expectations. The Danish group reports that this product, potential successor to Wegovy, brought a weight loss of 22.7%, against 25% expected, in the Redefine 1 clinical trial. CagriSema is a weekly injection which combines the active ingredient semaglutide from Wegovy, with another molecule, cagrilintide.
The laboratory emphasizes, however, that the trial achieved its primary endpoint by demonstrating statistically significant weight loss superior to placebo over 68 weeks. The most common adverse reactions were gastrointestinal, and the vast majority were mild to moderate and diminished over time.
Results from the second pivotal phase 3 trial, Redefine 2, in adults with type 2 diabetes, obesity or overweight, are expected during the first half of 2025.
Main competitor of Novo Nordisk in this market of weight loss drugs, the American Eli Lilly is expected to increase by more than 10% in pre-market on Wall Street.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article? Share it with your friends using the buttons below.
